• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    FitLife Brands Announces First Quarter 2025 Results

    5/15/25 7:30:00 AM ET
    $FTLF
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $FTLF alert in real time by email

    OMAHA, NE, May 15, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the first quarter ended March 31, 2025.

    Highlights for the first quarter ended March 31, 2025 include:

    • Total revenue was $15.9 million, 4% lower than the first quarter of 2024.  
    • Online sales were $10.6 million, representing 67% of total revenue and down 2% compared to the first quarter of 2024.
    • Gross margin was 43.1% compared to 44.0% during the first quarter of 2024.
    • Net income for the first quarter of 2025 was $2.0 million compared to $2.2 million during the same period last year.
    • Basic earnings per share and diluted earnings per share were $0.22 and $0.20, respectively, compared to $0.23 and $0.21 for the first quarter of 2024.
    • Adjusted EBITDA was $3.4 million, a 6% decrease compared to the first quarter of 2024.
    • The Company ended the quarter with $12.0 million outstanding on its term loans and cash of $6.0 million, or total net debt of $6.0 million, equivalent to approximately 0.4x adjusted EBITDA.



    For the first quarter ended March 31, 2025, total revenue decreased 4% to $15.9 million compared to $16.5 million during the same period last year. Online revenue for the quarter was $10.6 million, down 2% compared to the quarter ended March 31, 2024. Online revenue accounted for 67% and 65% of the Company's total revenue during the quarters ended March 31, 2025 and 2024, respectively.   Wholesale revenue for the quarter ended March 31, 2025 was $5.3 million, a 7% decrease when compared to the same period last year.  

    Gross margin for the quarter ended March 31, 2025 was 43.1% compared to 44.0% during the same period in the prior year.

    Net income for the first quarter of 2025 was $2.0 million compared to $2.2 million during the quarter ended March 31, 2024. Basic earnings per share and diluted earnings per share were $0.22 and $0.20, respectively, compared to $0.23 and $0.21 for the first quarter of 2024. Excluding the impact of elevated merger- and acquisition-related expense for the first quarter of 2025, net income and earnings per share would have been comparable or higher than during the first quarter of 2024.

    Adjusted EBITDA for the quarter ended March 31, 2025 was $3.4 million, a decrease of 6% compared to the same period in 2024, bringing adjusted EBITDA for the trailing twelve months to $13.9 million.

    The Company ended the quarter with $12.0 million outstanding on its term loans, no outstanding balance on its line of credit, and cash of $6.0 million, or total net debt of $6.0 million.  

    Performance of Acquired Brands

    One of the primary metrics used by management to evaluate the performance of the Company's brands is contribution, a non-GAAP financial measure which management defines as gross profit less advertising and marketing expenditures. Other companies may also report contribution as a performance metric, but their definition or calculation of contribution may differ from the Company's. Management believes that contribution, as defined by the Company, is a particularly relevant performance metric since it incorporates the gross profit associated with a specific brand or collection of brands as well as the advertising and marketing expenditures associated with the same brand or brands. With limited exceptions, other operating expense incurred by the Company is generally not allocable to a specific brand or collection of brands.

    Management intends to provide this level of disclosure for acquired brands for no more than two years following a transaction, after which the performance of acquired brands will be reported as part of Legacy FitLife results. Other than for MusclePharm, the numbers in the contribution tables presented below in the body of this press release represent the performance of a collection of brands. Legacy FitLife consists of nine brands and MRC consists of three brands. These collections of brands do not meet the definition of operating segments and are not managed as such.

    Legacy FitLife      
    (Unaudited)      
     2024

     2025 
     Q1Q2Q3Q4 Q1
     Wholesale revenue4,506 4,224 3,859 3,210  4,585 
     Online revenue2,455 2,578 2,443 2,112  2,714 
     Total revenue6,961 6,802 6,302 5,322  7,299 
     Gross profit2,928 3,006 2,684 2,115  3,254 
    Gross margin42.1%44.2%42.6%39.7% 44.6%
    Advertising and marketing80 94 70 59  85 
    Contribution2,848 2,912 2,614 2,056  3,169 
    Contribution as a % of revenue40.9%42.8%41.5%38.6% 43.4%



    For the first quarter of 2025, Legacy FitLife revenue increased 5% compared to the same period last year, driven by an 11% increase in online revenue and a 2% increase in wholesale revenue.

    Gross profit and contribution for Legacy FitLife both increased by 11% compared to the same period last year. Gross margin increased from 42.1% during the first quarter of 2024 to 44.6% during the first quarter of 2025. Contribution as a percentage of revenue increased from 40.9% to 43.4% over the same time period.

    Mimi's Rock (MRC)      
    (Unaudited)      
       2024   2025 
     Q1Q2Q3Q4 Q1
     Wholesale revenue94 90 71 40  63 
     Online revenue7,399 7,371 7,139 6,832  6,611 
     Total revenue7,493 7,461 7,210 6,872  6,674 
     Gross profit3,520 3,597 3,441 3,350  3,030 
    Gross margin47.0%48.2%47.7%48.7% 45.4%
    Advertising and marketing1,062 1,071 929 803  794 
    Contribution2,458 2,526 2,512 2,547  2,236 
    Contribution as % of revenue32.8%33.9%34.8%37.1% 33.5%
           

    For the first quarter of 2025, MRC revenue decreased 11% compared to the same period in 2024. Revenue for the largest MRC brand, Dr. Tobias, decreased 11% while revenue for the skin care brands, Maritime Naturals and All Natural Advice, declined 14% (or 9% on a constant currency basis) for the first quarter of 2025 compared to the same period in 2024.   

    For MRC, gross profit declined 14% and contribution declined 9%. Gross margin declined to 45.4% compared to 47.0% in the first quarter of 2024. Contribution as a percentage of revenue increased to 33.5% compared to 32.8% during the first quarter of 2024.

    The decrease in gross profit for the MRC brands is primarily the result of lower sales. The decrease in gross margin is primarily driven by the change in product mix within the Dr. Tobias brand. The year-over-year increase in contribution as a percentage of revenue for the MRC brands is the result of continued optimization of advertising spend across all MRC brands.

    MusclePharm      
    (Unaudited)      
       2024   2025 
     Q1Q2Q3Q4 Q1
     Wholesale revenue1,117 1,388 1,231 1,689  658 
     Online revenue978 1,279 1,234 1,130  1,305 
     Total revenue2,095 2,667 2,465 2,819  1,963 
     Gross profit839 977 876 747  590 
    Gross margin40.0%36.6%35.5%26.5% 30.1%
    Advertising and marketing86 161 94 117  174 
    Contribution753 816 782 630  416 
    Contribution as % of revenue35.9%30.6%31.7%22.3% 21.2%
           

    For the first quarter of 2025, MusclePharm revenue decreased 6% compared to the same period last year, with wholesale revenue decreasing 41% and online revenue increasing 33%. As previously disclosed, in an effort to drive revenue growth, the Company is making targeted investments in advertising and promotion in both the wholesale and online channels. During the fourth quarter of 2024, the Company offered additional promotional incentives to certain wholesale partners in an effort to drive incremental growth for the MusclePharm brand.  The decrease in wholesale revenue during the quarter was primarily due to one wholesale customer that took advantage of the Company's promotional investment during the fourth quarter of 2024 without increasing their sell-through of the product, which affected their reorder volumes during the first quarter of 2025.

    In mid-March 2025, the Company launched the new MusclePharm Pro Series, a collection of premium sports nutrition products, in a pilot in high-volume Vitamin Shoppe stores (consisting of approximately 60% of Vitamin Shoppe's nationwide store base). If the pilot effort is successful, the Pro Series is anticipated to be added to the assortment in all Vitamin Shoppe stores and will be exclusive to Vitamin Shoppe for a period of 12 months.

    As part of these and other efforts to drive revenue growth, the Company is making targeted investments in advertising and promotion for the MusclePharm brand in both the wholesale and online channels. As a result of these investments, gross margin and contribution margin as a percentage of revenue may fluctuate from quarter to quarter.

    FitLife Consolidated      
    (Unaudited)      
       2024   2025 
     Q1Q2Q3Q4 Q1
           
     Wholesale revenue5,717 5,702 5,161 4,939  5,306 
     Online revenue10,832 11,228 10,816 10,074  10,630 
     Total revenue16,549 16,930 15,977 15,013  15,936 
     Gross profit7,287 7,580 7,001 6,212  6,874 
    Gross margin44.0%44.8%43.8%41.4% 43.1%
    Advertising and marketing1,228 1,326 1,093 979  1,053 
    Contribution6,059 6,254 5,908 5,233  5,821 
    Contribution as % of revenue36.6%36.9%37.0%34.9% 36.5%
           

    For the Company overall, revenue decreased 4%, gross profit decreased 6%, and contribution decreased 4% compared to the first quarter of 2024. Gross margin declined to 43.1% compared to 44.0% during the first quarter last year. Contribution as a percentage of revenue decreased slightly to 36.5% compared to 36.6% during the first quarter last year.

    Management Commentary

    Dayton Judd, the Company's Chairman and CEO commented, "As previously disclosed, the first quarter of 2025 was strong for our Legacy FitLife business, but somewhat challenged for MRC and MusclePharm.   With regard to Legacy FitLife, we benefitted from a slight increase in wholesale revenue and strong growth in online revenue, which is the most profitable part of our business. These dynamics helped to drive very encouraging increases in gross margin and contribution as a percentage of revenue for Legacy FitLife.

    "Wholesale revenue for MusclePharm declined primarily due to reduced purchases from a large customer that took advantage of the increased promotional incentives we offered during the fourth quarter but was not successful in achieving increased sell-through of our products. Orders from this customer thus far during the second quarter of 2025 are higher than for all of the first quarter of 2025. Much of the decline in wholesale revenue for the quarter was offset by strong growth in MusclePharm's online revenue.

    "With regard to MRC's online revenue, we have previously highlighted the challenging year-over-year comparisons that began in February of 2025 for the Dr. Tobias brand. In January, online revenue for Dr. Tobias increased slightly. February was the most challenging month, with online revenue down 16%, followed by a 12% decline in March.

    "One benefit of owning a portfolio of brands is that strong performance by some brands can help offset weaker performance by others. For much of 2024, strong performance by Dr. Tobias helped to offset challenges we were experiencing with some of the Legacy FitLife brands. Thus far in 2025, we are seeing the inverse of that.

    "On a consolidated basis, we are encouraged by the Company's continued strong cash flow generation, which has allowed for further deleveraging of the balance sheet. On a net debt basis, our leverage is now approximately only 0.4x adjusted EBITDA for the trailing twelve months, and the Company has the financial flexibility to complete a sizable acquisition should a compelling opportunity arise.   The current market environment has resulted in elevated deal flow, and we continue to review a number of M&A opportunities."

    Earnings Conference Call

    The Company will hold an investor conference call on Thursday, May 15, 2025 at 4:30 pm ET. Investors interested in participating in the live call can dial (833) 492-0064 from the U.S. and provide the conference identification code of 577011. International participants can dial (973) 528-0163 and provide the same code.

    About FitLife Brands

    FitLife Brands is a developer and marketer of innovative and proprietary nutritional supplements and wellness products for health-conscious consumers. FitLife markets more than 250 different products primarily online, but also through domestic and international GNC® franchise locations as well as through various retail locations. FitLife is headquartered in Omaha, Nebraska. For more information, please visit our website at www.fitlifebrands.com.

    Forward-Looking Statements

    Statements in this release that are forward looking involve known and unknown risks and uncertainties, which may cause the Company's actual results in future periods to be materially different from any future performance that may be suggested in this news release. Such factors may include, but are not limited to, the ability of the Company to continue to grow revenue, and the Company's ability to continue to achieve positive cash flow given the Company's existing and anticipated operating and other costs. Many of these risks and uncertainties are beyond the Company's control. Reference is made to the discussion of risk factors detailed in the Company's filings with the Securities and Exchange Commission including its reports on Form 10-K and 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the dates on which they are made.

    FITLIFE BRANDS, INC.

    CONDENSED CONSOLIDATED BALANCE SHEETS

    (In thousands, except per share data)

      March 31,

    2025
      December 31,

    2024
     
    ASSETS: (Unaudited)     
    CURRENT ASSETS        
    Cash and cash equivalents $5,941  $4,468 
    Restricted cash  53   52 
    Accounts receivable, net of allowance for credit losses of $38 and $41, respectively  2,693   1,626 
    Inventories, net of allowance for obsolescence of $76 and $100, respectively  12,131   11,074 
    Prepaid expense and other current assets  941   923 
    Total current assets  21,759   18,143 
             
    Property and equipment, net  89   75 
    Right of use asset  385   412 
    Intangibles, net of amortization of $161 and $152, respectively  26,234   26,235 
    Goodwill  13,035   13,022 
    Deferred tax asset  691   644 
    TOTAL ASSETS $62,193  $58,531 
             
    LIABILITIES AND STOCKHOLDERS' EQUITY:        
    CURRENT LIABILITIES:        
    Accounts payable $5,275  $4,067 
    Accrued liabilities  1,121   684 
    Income taxes payable  1,745   1,415 
    Product returns  574   564 
    Term loan – current portion  4,500   4,500 
    Lease liability – current portion  81   81 
    Total current liabilities  13,296   11,311 
    Term loan, net of current portion and unamortized deferred finance costs  7,436   8,550 
    Long-term lease liability, net of current portion  312   331 
    Deferred tax liability  2,231   2,213 
    TOTAL LIABILITIES  23,275   22,405 
             
    STOCKHOLDERS' EQUITY:        
    Preferred stock, $0.01 par value, 10,000 shares authorized, none outstanding as of March 31, 2025 and December 31, 2024  -   - 
    Common stock, $0.01 par value, 120,000 shares authorized; 9,383 and 9,210 issued and outstanding as of March 31, 2025 and December 31, 2024, respectively  94   92 
    Additional paid-in capital  31,872   31,129 
    Retained earnings  7,585   5,567 
    Foreign currency translation adjustment  (633)  (662)
    TOTAL STOCKHOLDERS' EQUITY  38,918   36,126 
    TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $62,193  $58,531 



    FITLIFE BRANDS, INC. 

    CONDENSED CONSOLIDATED STATEMENTS OF INCOME

    (In thousands, except per share data)

    (Unaudited)

      Three months ended March 31, 
      2025  2024 
             
    Revenue $15,936  $16,549 
    Cost of goods sold  9,062   9,262 
    Gross profit  6,874   7,287 
             
    OPERATING EXPENSE:        
    Advertising and marketing  1,053   1,228 
    Selling, general and administrative  2,512   2,508 
    Merger and acquisition related  332   134 
    Depreciation and amortization  19   36 
    Total operating expense  3,916   3,906 
    OPERATING INCOME  2,958   3,381 
             
    OTHER EXPENSE (INCOME)        
    Interest income  (26)  (5)
    Interest expense  244   414 
    Foreign exchange loss  21   5 
    Total other expense, net  239   414 
    INCOME BEFORE INCOME TAX PROVISION  2,719   2,967 
             
    PROVISION FOR INCOME TAXES  701   807 
             
    NET INCOME $2,018  $2,160 
             
    NET INCOME PER SHARE        
    Basic $0.22  $0.23 
    Diluted $0.20  $0.21 
    Basic weighted average common shares  9,213   9,196 
    Diluted weighted average common shares  9,926   10,060 



    FITLIFE BRANDS, INC. 

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    (In thousands)

    (Unaudited)

      Three months ended March 31, 
      2025  2024 
             
    CASH FLOWS FROM OPERATING ACTIVITIES:        
    Net income $2,018  $2,160 
    Adjustments to reconcile net income to net cash provided by operating activities:        
    Depreciation and amortization  19   36 
    Allowance for credit losses  (3)  1 
    Allowance for inventory obsolescence  (24)  (23)
    Stock-based compensation  107   102 
    Amortization of deferred financing costs  11   10 
             
    Changes in operating assets and liabilities:        
    Accounts receivable  (1,062)  (242)
    Inventories  (1,013)  218 
    Deferred taxes  (47)  180 
    Prepaid expense and other current assets  362   1,067 
    Right of use asset  27   21 
    Accounts payable  1,168   727 
    Income taxes payable  318   56 
    Lease liability  (20)  (30)
    Accrued liabilities  449   800 
    Product returns  18   (47)
    Net cash provided by operating activities  2,328   5,036 
             
    CASH FLOWS FROM INVESTING ACTIVITIES:        
    Purchase of property and equipment  (24)  (10)
    Net cash used in investing activities  (24)  (10)
             
    CASH FLOWS FROM FINANCING ACTIVITIES:        
    Payments on term loans  (1,125)  (3,625)
    Proceeds from exercise of stock options  259   - 
    Net cash used in financing activities  (866)  (3,625)
             
    Foreign currency impact on cash  36   (9)
             
    CHANGE IN CASH AND RESTRICTED CASH  1,474   1,392 
    CASH AND RESTRICTED CASH, BEGINNING OF PERIOD  4,520   1,898 
    CASH AND RESTRICTED CASH, END OF PERIOD $5,994  $3,290 
             
    Supplemental cash flow disclosure        
    Cash paid for income taxes $408  $168 
    Cash paid for interest $238  $417 

    Non-GAAP Measures

    The financial presentation below contains certain financial measures not in accordance with GAAP, defined by the SEC as "non-GAAP financial measures", including EBITDA and adjusted EBITDA. These measures may be different from non-GAAP financial measures used by other companies. The presentation of this financial information, which is not prepared under any comprehensive set of accounting rules or principles, is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in this Quarterly Report in accordance with GAAP.

    As presented below, EBITDA excludes interest, foreign exchange gains and losses, income taxes, and depreciation and amortization. Adjusted EBITDA excludes—in addition to interest, foreign exchange losses, taxes, depreciation and amortization—stock-based compensation and merger and acquisition related expense. The Company believes the non-GAAP measures provide useful information to both management and investors by excluding certain expense and other items that may not be indicative of its core operating results and business outlook. The Company believes that the inclusion of non-GAAP measures in the financial presentation below allows investors to compare the Company's financial results with the Company's historical financial results and is an important measure of the Company's comparative financial performance.

      For the three months ended March 31, 
      2025  2024 
      (Unaudited)  (Unaudited) 
    Net income $2,018  $2,160 
    Interest expense  244   414 
    Interest income  (26)  (5)
    Foreign exchange loss  21   5 
    Provision for income taxes  701   807 
    Depreciation and amortization  19   36 
    EBITDA  2,977   3,417 
    Non-cash and non-recurring adjustments        
    Stock compensation expense  107   102 
    Merger and acquisition related expense  332   134 
    Adjusted EBITDA $3,416  $3,653 







    [email protected]

    Primary Logo

    Get the next $FTLF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FTLF

    DatePrice TargetRatingAnalyst
    3/17/2025$21.00Buy
    Lake Street
    9/3/2024$40.00Buy
    ROTH MKM
    More analyst ratings

    $FTLF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • FitLife Brands Announces First Quarter 2025 Results

      OMAHA, NE, May 15, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the first quarter ended March 31, 2025. Highlights for the first quarter ended March 31, 2025 include: Total revenue was $15.9 million, 4% lower than the first quarter of 2024.  Online sales were $10.6 million, representing 67% of total revenue and down 2% compared to the first quarter of 2024.Gross margin was 43.1% compared to 44.0% during the first quarter of 2024.Net income for the first quarter of 2025 was $2.0 million compared to $2.2 million during th

      5/15/25 7:30:00 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care
    • FitLife Brands Announces First Quarter Earnings Call

      OMAHA, NE, May 05, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife," or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced that it plans to report its financial performance for the first quarter of fiscal 2025 on Thursday, May 15, 2025. In addition, the Company announced that it will hold an investor conference call after market close on May 15, 2025 at 4:30 pm ET.  Investors interested in participating in the live call can dial (833) 492-0064 from the U.S. and provide the conference identification code of 577011.  International participants can dial (973) 528-0163 and provide the same code. About

      5/5/25 3:00:00 PM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care
    • FitLife Brands Announces Board Transition

      Omaha, NE, April 28, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, announced today the resignation of Todd Ordal as a member of the Company's Board of Directors. Mr. Ordal's resignation, effective on April 25, 2025, was part of the Company's ongoing commitment to refresh board composition on a regular basis in accordance with good corporate governance practices and was not the result of any disagreement with the Company's management or the Board of Directors regarding any matter related to the Company or otherwise. On April 25, 2025, the Board of Directors of

      4/28/25 7:30:00 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care

    $FTLF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Hansen Ryan P. claimed ownership of 25,678 shares (SEC Form 3)

      3 - FITLIFE BRANDS, INC. (0001374328) (Issuer)

      5/12/25 7:27:11 PM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form 3 filed by new insider Pappas Shannon K.

      3 - FITLIFE BRANDS, INC. (0001374328) (Issuer)

      5/12/25 7:26:27 PM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Ordal Todd bought $3,621 worth of shares (300 units at $12.07), increasing direct ownership by 0.48% to 62,488 units (SEC Form 4)

      4 - FITLIFE BRANDS, INC. (0001374328) (Issuer)

      4/16/25 8:00:07 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care

    $FTLF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ordal Todd bought $3,621 worth of shares (300 units at $12.07), increasing direct ownership by 0.48% to 62,488 units (SEC Form 4)

      4 - FITLIFE BRANDS, INC. (0001374328) (Issuer)

      4/16/25 8:00:07 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Lingenbrink Matthew bought $36,510 worth of shares (3,000 units at $12.17), increasing direct ownership by 107% to 5,800 units (SEC Form 4)

      4 - FITLIFE BRANDS, INC. (0001374328) (Issuer)

      4/16/25 8:00:05 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Lingenbrink Matthew bought $34,089 worth of shares (2,800 units at $12.17) (SEC Form 4)

      4 - FITLIFE BRANDS, INC. (0001374328) (Issuer)

      4/2/25 8:01:06 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care

    $FTLF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Lake Street initiated coverage on FitLife Brands with a new price target

      Lake Street initiated coverage of FitLife Brands with a rating of Buy and set a new price target of $21.00

      3/17/25 8:22:47 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care
    • ROTH MKM initiated coverage on FitLife Brands with a new price target

      ROTH MKM initiated coverage of FitLife Brands with a rating of Buy and set a new price target of $40.00

      9/3/24 7:48:49 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care

    $FTLF
    SEC Filings

    See more
    • Amendment: SEC Form 10-K/A filed by FitLife Brands Inc.

      10-K/A - FITLIFE BRANDS, INC. (0001374328) (Filer)

      4/28/25 6:43:29 PM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care
    • FitLife Brands Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

      8-K - FITLIFE BRANDS, INC. (0001374328) (Filer)

      4/28/25 8:00:11 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care
    • FitLife Brands Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - FITLIFE BRANDS, INC. (0001374328) (Filer)

      4/22/25 7:30:15 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care

    $FTLF
    Financials

    Live finance-specific insights

    See more
    • FitLife Brands Announces First Quarter 2025 Results

      OMAHA, NE, May 15, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the first quarter ended March 31, 2025. Highlights for the first quarter ended March 31, 2025 include: Total revenue was $15.9 million, 4% lower than the first quarter of 2024.  Online sales were $10.6 million, representing 67% of total revenue and down 2% compared to the first quarter of 2024.Gross margin was 43.1% compared to 44.0% during the first quarter of 2024.Net income for the first quarter of 2025 was $2.0 million compared to $2.2 million during th

      5/15/25 7:30:00 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care
    • FitLife Brands Announces First Quarter Earnings Call

      OMAHA, NE, May 05, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife," or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced that it plans to report its financial performance for the first quarter of fiscal 2025 on Thursday, May 15, 2025. In addition, the Company announced that it will hold an investor conference call after market close on May 15, 2025 at 4:30 pm ET.  Investors interested in participating in the live call can dial (833) 492-0064 from the U.S. and provide the conference identification code of 577011.  International participants can dial (973) 528-0163 and provide the same code. About

      5/5/25 3:00:00 PM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care
    • FitLife Brands Announces Fourth Quarter and Full-Year 2024 Results

      Omaha, March 27, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced financial results for the fourth quarter and full year ended December 31, 2024. Highlights for the fourth quarter ended December 31, 2024 include: Total revenue was $15.0 million, an increase of 13% compared to the fourth quarter of 2023.  Online sales were $10.1 million, representing 67% of total revenue and an increase of 12% compared to the fourth quarter of 2023.Gross margin was 41.4% compared to 40.3% during the fourth quarter of 2023.Net income was $2.1 million compared to $

      3/27/25 7:30:00 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care

    $FTLF
    Leadership Updates

    Live Leadership Updates

    See more
    • FitLife Brands Announces Board Transition

      Omaha, NE, April 28, 2025 (GLOBE NEWSWIRE) -- FitLife Brands, Inc. ("FitLife" or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, announced today the resignation of Todd Ordal as a member of the Company's Board of Directors. Mr. Ordal's resignation, effective on April 25, 2025, was part of the Company's ongoing commitment to refresh board composition on a regular basis in accordance with good corporate governance practices and was not the result of any disagreement with the Company's management or the Board of Directors regarding any matter related to the Company or otherwise. On April 25, 2025, the Board of Directors of

      4/28/25 7:30:00 AM ET
      $FTLF
      Medicinal Chemicals and Botanical Products
      Health Care
    • LifeVantage Appoints Dayton Judd to the Board of Directors

      SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (NASDAQ:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Dayton Judd to the Company's Board of Directors (the "Board"), effective immediately, in an expansion of the Board. The Company has had discussions with Bradley L. Radoff and Sudbury Capital Fund, LP (collectively with certain of their affiliates, the "Radoff-Sudbury Group"), which owns approximately 12.6% of the Company's outstanding stock, since the Company's fiscal year 2024 annual meeting of shareholders held on November 6, 2023. During these dis

      2/15/24 4:05:00 PM ET
      $FTLF
      $LFVN
      $OPXS
      Medicinal Chemicals and Botanical Products
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Electronic Components